NASDAQ:NGM
NGM Biopharmaceuticals Inc. Stock News
$1.54
+0 (+0%)
At Close: May 16, 2024
NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
07:00am, Monday, 24'th May 2021
SOUTH SAN FRANCISCO, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutic
NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
06:00pm, Sunday, 23'rd May 2021
SOUTH SAN FRANCISCO, Calif., May 23, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30 a.m.
NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Tops Revenue Estimates
09:02pm, Thursday, 06'th May 2021
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 14.29% and 1.17%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: NGM Biopharmaceuticals (NGM) Q1 Earnings Expected to Decline
04:10pm, Wednesday, 05'th May 2021
NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors
04:15pm, Wednesday, 28'th Apr 2021
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeut
Strength Seen in NGM Biopharmaceuticals (NGM): Can Its 6.7% Jump Turn into More Strength?
12:07pm, Friday, 26'th Mar 2021
NGM Biopharmaceuticals (NGM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mo
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
08:28pm, Thursday, 04'th Mar 2021
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 14.89% and -14.45%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the sto
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results
04:05pm, Thursday, 04'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeut
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeuti
NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock
09:55pm, Tuesday, 05'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeuti
NGM Bio Announces Proposed Offering of Common Stock
04:01pm, Monday, 04'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeuti
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeuti
NGM to Host Virtual R&D Day on December 9, 2020
12:05pm, Monday, 16'th Nov 2020
– Event to showcase NGM's multi-therapeutic area p ipeline , including its oncology por tfolio and Geographic Atrophy and NASH programs –
--Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intraocular in
NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results
04:05pm, Thursday, 12'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeuti
